Clinical Trial Update: Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers [Phase 1]

View source ↗

Summary

This report covers Phase I-II multi-dose safety and efficacy data for a selective COX-2 inhibitor, SC-58635, in patients with hereditary nonpolyposis colorectal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Lynch Syndrome

Drugs mentioned

• SC-58635

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Colorectal Neoplasm, Hereditary Nonpolyposis | Phase 1 | Status: COMPLETED